Discovery of a novel rhein-SAHA hybrid as a multi-targeted anti-glioblastoma drug
| Autor: | Rongbiao Pi, Jingkao Chen, Bingling Luo, Shijun Wen |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Biological Availability Anthraquinones Antineoplastic Agents Protein Serine-Threonine Kinases Hydroxamic Acids Histone Deacetylases Immediate-Early Proteins 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Cell Movement Cell Line Tumor Humans Neoplasm Invasiveness Pharmacology (medical) U87 Protein kinase A Cell Proliferation Pharmacology Vorinostat Hydroxamic acid Biological activity Glioma In vitro Histone Deacetylase Inhibitors 030104 developmental biology Oncology chemistry Cell culture 030220 oncology & carcinogenesis Cancer research SGK1 Histone deacetylase Glioblastoma |
| Zdroj: | Investigational New Drugs. 38:755-764 |
| ISSN: | 1573-0646 0167-6997 |
| DOI: | 10.1007/s10637-019-00821-4 |
| Popis: | Glioblastoma multiforme (GBM) is the most common malignant tumor of the central nervous system (CNS). Effective treatments remain limited. Therefore, novel chemotherapy drugs with high efficiency and few adverse effects are urgently needed. Histone deacetylase (HDAC) and serum and glucocorticoid-regulated protein kinase 1 (SGK1) are targets for the prevention and treatment of GBM. Rhein has antitumor and SGK1 suppression effects, although its biological activity is limited by poor bioavailability. To improve the drug-like properties of rhein, we constructed a novel rhein-hydroxyethyl hydroxamic acid derivative (SYSUP007), which combined rhein with the HDAC inhibitor, suberoylanilide hydroxamic acid (SAHA). In the present study, the human GBM cell lines, T98G, U87 and U251, were used to investigate the anticancer effects of SYSUP007 in vitro. We found that SYSUP007 was more effective in inhibiting glioma cell proliferation, invasion and migration in vitro compared with the effects of rhein and SAHA. We also confirmed that SYSUP007 increased the expression of Ac-K100 and NDRG1 (targets of HDAC and SGK1). The present study indicates the potential that SYSUP007, as a novel rhein and SAHA derivative, for development as an anti-cancer therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink